The study’s foundation was an examination of health data from 170,742 British citizens with dementia.
Who were over 55 and had used mirabegron or an anticholinergic medication for three to sixteen years prior to receiving a dementia diagnosis.
For the sake of comparison, each British person with dementia was paired with a member of an 800,000-strong control group based on their precise age, sex, and general practitioner’s practice.
The first of the study’s weaknesses was the absence of data about the precise amount given to patients.
Which prevented the scientists from thoroughly examining whether larger dosages of specific medications over time increased the risk of dementia.
Another was that the information was based on patient records, which may not have been accurate or comprehensive.
